US8143231B1ActiveUtility

Method of reducing HIV-replication in human body tissue

47
Individually held — no corporate assignee on recordPriority: Jul 18, 2008Filed: Jul 20, 2009Granted: Mar 27, 2012
Est. expiryJul 18, 2028(~2 yrs left)· nominal 20-yr term from priority
Inventors:Loyda M MelendezClaribel Luciano-Montalvo
A61K 31/7115
47
PatentIndex Score
0
Cited by
2
References
3
Claims

Abstract

Mononuclear phagocytes are reservoirs, vehicles of dissemination, and targets for persistent HIV infection. However, not all MP population equally support viral growth. Such differential replication is typified by the greater ability of placental macrophages (PM), as compared to blood borne monocyte-derived macrophages (MDM), to restrict viral replication. A SELDI-TOF protein peak with an m/z of 11,100 identified as cystatin B (CSTB), was significantly lower in uninfected and HIV-infected PM than in MDM. HIV replication can be reduced by down regulating the expression of Cystatin B.

Claims

exact text as granted — not AI-modified
1. A method of reducing HIV-Replication in human body tissue comprising specifically down regulating expression of Cystatin B gene in said human body tissue with a nucleic acid inhibitor. 
     
     
       2. The method of  claim 1 , where in said human body tissue comprises a placenta. 
     
     
       3. The method of  claim 1 , wherein said nucleic acid inhibitor is siRNA.

Join the waitlist — get patent alerts

Track US8143231B1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.